Treatment of FGF-mediated conditions by administration of a cardiac glycoside or aglycone derivative thereof
US6071885A · kind A · utility
15Cited by
3References
9Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 14, 1998 |
| Grant date | Jun 6, 2000 |
| Priority date | — |
| Expiry date | Dec 14, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1.alpha., IL-1.beta. and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.